Twelve Below

Twelve Below Research Investment Thesis Twelve Below is a pre-seed and seed-stage venture fund founded in 2021 to reshape the future of venture capital by operating as a true partner to founders. The fund was established by Byron Ling and Taylor Greene, two seasoned investors who spent the previous decade as partners at leading early-stage firms (Primary, Canaan, Lerer Hippeau, and Collaborative) where they built deep expertise in identifying breakthrough founders and guiding them through critical early-stage milestones. The fund explicitly positions itself as "your first true partner," earning the right to lead pre-seed and seed rounds before the broader market believes in the opportunity. They seek founders with secret insights about markets they're attacking, combined with obsessive focus on solving problems they can't unsee. The firm believes its primary value comes from hands-on partnership—providing seasoned insight, actionable guidance, and meaningful networks rather than operating through a platform model with operating staff. Fund Structure and Size Twelve Below closed two funds simultaneously in November 2023: Fund II : $80M dedicated to pre-seed and seed investments Opportunity Fund : $28M for follow-on opportunities Total AUM : $108M (as of November 2023) The fund was founded in 2021 and has been actively deploying capital, with recent investments through early 2026 (Barnwell Bio, January 2026). Stage Focus and Check Size Twelve Below exclusively targets pre-seed and seed-stage companies: Pre-seed : $1M-$3M checks Seed : $1M-$3M checks Ownership targets : 10-15% of core investments Typical check size : $1M-$3M The firm explicitly positions itself as often the "first institutional believer" and investor in portfolio companies. Investment Activity and Portfolio As of February 2026, Twelve Below has made 46+ investments across diverse sectors. Their portfolio demonstrates breadth across multiple industries: Healthcare & Biotech (largest concentration): Arya Health (AI-enabled clinical insights) Barnwell Bio (biotech) Caladan Bio (biotech) Carma Care (healthcare platform) Conduit Health (health services) For The Health (healthcare) Health Universe (health platform) Indie Health (telehealth/wellness) Solstice Health (mental health) Fintech & Commerce : Accrue Savings (financial wellness) Relay Commerce (commerce infrastructure) Dispatch (logistics/delivery) DraftBoard (sports/gaming fintech) AI & Software : ASAPI (AI tools) Rondah (AI healthcare) VoiceOps (voice operations) Page (productivity software, raised $4.1M CAD Series, March 2025) Energy : Odyssey Energy Solutions (clean energy) Other Sectors : Aston Labs (hardware/robotics) Lilo (unknown/emerging) Mento (mental health/productivity) Phase Lab (biotech/research tools) ShareWillow (fintech/wealth management) TrueHold (wealth management) Turbo (computing/AI infrastructure) Goodwin (consumer/platform) Forte Lessons (education/skills) Coral (health/wellness) Archetype (design/product tools) PetStable (pet commerce, Mexico) Recent verified investments include: Arya Health : Series A funding ($18M, October 2025) with Twelve Below involved Page Technologies : Seed round ($4.1M CAD, March 2025), led by Twelve Below Barnwell Bio : Seed investment (January 25, 2026) Sector Classification Twelve Below demonstrates sector diversity with particular strength in: Healthcare & Digital Health - Largest portfolio concentration with companies focused on AI-enabled healthcare, mental health, clinical infrastructure Fintech & Financial Services - Strong representation in financial wellness, payments, and wealth management AI/Software - Growing focus on AI-enabled tools and software-enabled businesses Biotech - Several biotech and life sciences investments Energy - Clean energy infrastructure (Odyssey) They explicitly focus on "software-enabled sector" businesses and typically avoid pure hardware or non-technical businesses. Team and Investment Process Core Leadership : Byron Ling, Partner : Former partner at Primary and Canaan, 10 years in venture. Notable prior board roles: Ro (telehealth), Papa (elder care), K Health (AI healthcare), Mirror/LULU (acquired, NASDAQ IPO), Italic (luxury), Osmind (neuroscience), Mantra Health (mental health). Seeks breakthrough ideas from founders with secret market insights. Taylor Greene, Partner : Former partner at Lerer Hippeau and Collaborative, 10 years in venture. Extensive board experience: Allbirds/BIRD (NASDAQ), Step (fintech), Mirror/LULU (acquired), Leaflink (cannabis B2B), Teamshares (commerce), Transfix (logistics), Monument (B2B), Guideline (fintech), Crexi (real estate), Parsec/U (NYSE), Hungryroot (delivery), OpenTrons (robotics), Loyal (alt proteins). Additional advisor roles at Mighty, Outbrain, Gyft, TrueHold, Dutch, Accrue, Sora Schools, Campus. Strong go-to-market expertise. Allison Kiang, Investor : Previously at Komodo Health building data products and analytics. BA in Neuroscience from Columbia. Looks for exceptional talent working on breakthrough ideas, focusing on systems design and product edges that create data moats. Tamar Vidra, Investor : Previously at Red Sea Ventures (NYC early-stage fund). Columbia University graduate. Seeks founders with earned market insights and category-defining visions. Decision Process : Partnership model with two founding partners making core investment decisions, supplemented by two investors (Kiang and Vidra). No investment committee mentioned; appears to be partnership-driven with clear decision authority. Investment Style and Values Twelve Below explicitly rejects the modern VC platform model in favor of a hands-on partnership approach: "Two founding partners handle all work directly rather than routing founders through operating staff" "True partners" who provide "the very first institutional check" Founder testimonials emphasize accessibility, tactical support, and quick responsiveness Notable founder quote: "They will get back to us within minutes no matter what time or day of the week, with honest, timeless advice" The fund provides: Strategic guidance and market insight Operational support through CEO relationships Network access (internal and external introductions) GTM and pricing strategy assistance Hire-related counsel and talent network Board participation and advisory roles Geographic Focus Primarily United States (New York headquartered), with some international presence: US-focused (primary market) Some investments in non-US markets (e.g., PetStable in Mexico) Network across SF Bay Area, NYC, and other tech hubs through team's prior affiliations Lead Tendency Leads : Twelve Below explicitly "lead or co-lead pre-seed and seed rounds," seeking 10-15% ownership in core investments. They position themselves as first institutional believer and lead investor. Decision Timeline Based on portfolio activity and stage focus: Appears to be 2-4 weeks for pre-seed/seed decisions. Not explicitly stated, but typical for early-stage partnership-driven funds with 4 decision-makers. Warm Introductions No explicit mention on website, but partnership-focused model with strong network suggests warm intros helpful but possibly not required. Byron and Taylor's extensive board networks and prior firm relationships provide significant connectivity. Typical Involvement Board seat : Typical for core portfolio companies Advisory : Active advisor and operator liaison Investor : Not passive; hands-on with post-investment engagement Founder testimonials highlight active partnership, not passive investment. Anti-Thesis Based on portfolio and website: No pure hardware plays No venture-scale B2C consumer apps without defensible tech/data advantages No gambling/gaming platforms (absent from portfolio despite size) No companies requiring heavy operational infrastructure beyond founder expertise Not interested in "platform VC" relationships where fund operates as service provider Notable Portfolio Exits and Returns Not extensively detailed on website, but based on founder board experience: Partners' board experience includes multiple acquisitions and at least one NASDAQ IPO (Mirror -> LULU, Allbirds -> BIRD, Parsec -> NYSE) Fund too young (founded 2021) for major exits; primarily focused on capital deployment and portfolio building Founder Preferences Based on team statements and portfolio composition: Clarity of thought and "deep chip on shoulder" Obsessive focus on solving a specific problem Secret insights about markets (non-obvious opportunities) Experienced founders or founders with domain expertise Technical ability (clear from dev tools, biotech, AI focus) Founder-driven rather than traditional MBA backgrounds Preference for founders they can truly partner with and support through early scaling Fund Status and Recent Activity Fund Status : Actively deploying from Fund II (closed November 2023) Latest known investment: Barnwell Bio (January 25, 2026) Estimated deployment rate: 40+ investments over ~2.5 years = ~16-18 investments/year Fund II ($80M) likely has 3-4 years of remaining deployment window Recent Investments (2025-2026) : January 2026: Barnwell Bio (seed) October 2025: Arya Health (Series A participation, though primarily seed-focused) March 2025: Page Technologies (seed round lead, $4.1M CAD) Ongoing: Portfolio monitoring and follow-on opportunities Competitive Positioning Twelve Below positions against: Large platform VCs (they explicitly reject platform model) Arms-length institutional VCs (they emphasize hands-on partnership) Sector-specific funds (they maintain sector diversity) Geographic specialists (they're NYC-based but network-distributed) Unique differentiators: Partnership approach : Only 2 GPs managing all relationships Experience pedigree : Combined 20+ years at leading early-stage firms Track record : Portfolio of experienced founders and multiple IPO/acquisition exits Accessibility : Non-traditional for VC (responsive, founder-centric) Sector diversity : Healthcare, fintech, AI, biotech, energy across portfolio